



DOCKET: CU-2642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Petr Jakovlevich Gaponyuk et al.)
)
SERIAL NO: 09/936,470) Group Art Unit: 1646
)
FILED: December 18, 2001) Examiner: Ruixiang Li

TITLE: ANTIVIRAL AGENT IN THE FORM
OF NOSE DROPS

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

CLEAN VERSION OF CLAIMS

RECEIVED

OCT 15 2002

TECH CENTER 1600/2900

14. An antiviral drug presented as nasal drops comprising genetically engineered alpha, beta or gamma interferon, at least one biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone and polyethylene oxide, and a biocompatible antioxidant, the drug viscosity being 11 – 300 Pa*s.
15. The antiviral drug of claim 14 wherein the antioxidant is Trilon B.
16. The antiviral drug of claim ¹14 or claim ²15 comprising polyvinyl pyrrolidone and polyethylene oxide in a ratio of 1:1 to 1:50.
17. An antiviral drug presented as nasal drops comprising per ml of a buffered saline solution:
- | | |
|--|--------------------|
| a. genetically engineered alpha, beta or gamma interferon | 1,000 – 300,000 IU |
| b. at least one biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone and polyethylene oxide | 0.005 – 0.714 g |
| c. antioxidant | 0.0001 – 0.0008 g |
- the drug viscosity being 11 – 300 Pa*s.
18. The antiviral drug of claim 17 wherein the antioxidant is Trilon B.
19. The antiviral drug of claim ⁴17 or claim ⁵18 comprising polyvinyl pyrrolidone and polyethylene oxide.

B1
cont.

7
20.

4

5

The antiviral drug of claim ~~17~~ or claim ~~18~~ comprising polyvinyl pyrrolidone and polyethylene oxide in a ratio of 1:1 to 1:50.
